Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy

Trial Profile

Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2015

At a glance

  • Drugs Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms HYDRIC
  • Most Recent Events

    • 28 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 11 Aug 2014 Status changed from not yet recruiting to recruiting, as per European Clinical Trials Database record.
    • 27 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top